BACKGROUND. Neoantigen-driven recognition and T cell–mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8⁺ T cells derived from TIL infusion products affect patient outcome is not fully determined.

中文翻译：

---

新抗原反应性 CD8+ T 细胞影响黑色素瘤中肿瘤浸润淋巴细胞过继细胞治疗的临床结果

背景。新抗原驱动的识别和 T 细胞介导的杀伤有助于肿瘤浸润淋巴细胞 (TIL) 过继细胞治疗 (ACT) 后的肿瘤清除。然而，源自 TIL 输注产品的扩增的新表位特异性 CD8 ^{+ T 细胞的多样性、频率和持久性如何影响患者的预后尚未完全确定。}